Decision analysis modelling of costs and outcomes following defepime monotherapy in Canada

Michael T. Halpern; Michael T. Halpern; RE Brown; M Drolet; SV Sorensen; LA Mandell

Decision analysis modelling of costs and outcomes following defepime monotherapy in Canada

Halpern, M., Brown, RE., Drolet, M., Sorensen, SV., & Mandell, LA. (1997). Decision analysis modelling of costs and outcomes following defepime monotherapy in Canada. Canadian Journal of Infectious Diseases & Medical Microbiology, 8(1), 19-27. http://www.pulsus.com/journals/abstract.jsp?sCurrPg=abstract&jnlKy=3&atlKy=2655&isuKy=656&isArt=t&fromfold=

Copy citation

Abstract

OBJECTIVE: To evaluate the comparative cost of treatment and intermediate outcomes (percentage resistant organisms, days in hospital, etc) among cefepime and alternative parenteral antibiotics used for empiric monotherapy.

DESIGN: Decision analysis model, based on published literature, clinical trial results and information from infectious disease clinicians.

SETTING: A Canadian tertiary care hospital.

INTERVENTION: Comparison of cefepime, ceftazidime, ceftriaxone, cefotaxime and ciprofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, skin/soft tissue infections, septicemia and febrile neutropenia.

MAIN RESULTS: Cefepime treatment results in the lowest average cost per patient when used as initial empiric therapy for lower respiratory tract infections and for skin/soft tissue infections. Cefepime therapy is among the lowest cost treatments for the other infectious disease conditions and has the lowest cost for a weighted 'average' condition. Sensitivity analysis indicates that model results are most sensitive to duration of hospitalization.

CONCLUSIONS: Initial empiric monotherapy with cefepime for serious infectious disease conditions may result in cost savings compared with alternative parenteral agents.